Still's disease, also known as Adult-onset Still's Disease (AOSD), is a rare inflammatory disease characterized by joint pain, rash, and fever. This devastating condition can lead to long-term chronic arthritis and permanent injuries. Still's disease is associated with a rash that does not itch and a high fever. This disorder can destroy the affected joints, especially the wrists. Treatment for Still's disease includes anti-inflammatory medications. Still's disease is a rare rheumatic disease. This disease is characterized by biological and clinical symptoms such as high fever, joint swelling, myalgia, sore throat, increase in white blood cells (leukocytes, especially neutrophils), and biological hepatitis. Treatment for Still's disease can be divided into two categories, namely symptomatic treatments and effective treatments. Symptomatic treatment can be started immediately even if the diagnosis is not confirmed, while effective treatment methods are designed to treat the disease more effectively to eliminate the symptoms of the disease.
Market Dynamics
Increasing practices of treatments, mergers, and acquisitions by key market players are expected to drive the global Still’s disease treatment market growth. For instance, on April 13, 2023, Metropolis Healthcare noted that treatment of Still's disease with nonsteroidal anti-inflammatory drugs (NSAIDs), these medications reduce inflammatory pain and the signs and symptoms of Still’s disease. Corticosteroids reduce inflammation by reducing the activity of the immune system. Disease-modifying Antirheumatic Drugs (DMARDs) can help slow down the progress of Still’s disease and reduce the frequency of flares. Physical therapy, exercise, rest, and a healthy diet can help manage the condition and keep symptoms to a minimum.
Key features of the study:
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook